Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide in NSCLC
NCT00157209Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2000
- Primary completion
- Mar 2006
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Aug 2000; status: completed.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00157209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157209.